Announced Sat, 30 May · 11:39 IST

Newspaper Publication of extracts of Audited Financial Results for the Fourth Quarter and Year ended on March 31, 2026.

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+4.4%1-day move
₹114.95
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+4.4+0.0+1.8+1.3+4.3+3.5-17.7-28.4
Up moveDown movePending
AI summary

Star Source Multi Trade Ltd (formerly Chemo Pharma Laboratories Limited) published extracts of its audited financial results for Q4 and FY 2025-26 in Business Standard and Mumbai Lakshdeep on May 30, 2026, in compliance with SEBI LODR Regulations. For the full year ended March 31, 2026, total revenue from operations was Rs. 534.26 lakhs, up 44.09% YoY from Rs. 370.77 lakhs in the prior year. Net profit after tax stood at Rs. 195.25 lakhs, surging 285% YoY from Rs. 50.70 lakhs. For Q4 FY26 alone, revenue was Rs. 131.21 lakhs and net profit was Rs. 31.15 lakhs. Equity share capital remains Rs. 1,897.677 lakhs, and EPS (basic and diluted) for the year was Rs. 0.10. The full financial results are available on the BSE website and the company's website.

Likely market impact

The company delivered strong double-digit growth in both revenue and profitability for FY2026, with net profit rising nearly 3x year-on-year, which is a positive signal for shareholders. The stock price could see upward movement on the back of these results.